Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials

Trial Profile

Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs GS 010 (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Adverse reactions; Registrational
  • Acronyms RESCUE; REVERSE
  • Sponsors GenSight Biologics
  • Most Recent Events

    • 29 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top